...
首页> 外文期刊>Advanced drug delivery reviews >Targeted nanoparticles with novel non-peptidic ligands for oral delivery
【24h】

Targeted nanoparticles with novel non-peptidic ligands for oral delivery

机译:具有新型非肽配体的靶向纳米颗粒,可用于口服给药

获取原文
获取原文并翻译 | 示例

摘要

Orally administered targeted nanoparticles have a large number of potential biomedical applications and display several putative advantages for oral drug delivery, such as the protection of fragile drugs or modification of drug pharmacokinetics. These advantages notwithstanding, oral drug delivery by nanoparticles remains challenging. The optimization of particle size and surface properties and targeting by ligand grafting have been shown to enhance nanoparticle transport across the intestinal epithelium. Here, different grafting strategies for non-peptidic ligands, e.g., peptidomimetics, lectin mimetics, sugars and vitamins, that are stable in the gastrointestinal tract are discussed. We demonstrate that the grafting of these non-peptidic ligands allows nanoparticles to be targeted to M cells, enterocytes, immune cells or L cells. We show that these grafted nanoparticles could be promising vehicles for oral vaccination by targeting M cells or for the delivery of therapeutic proteins. We suggest that targeting L cells could be useful for the treatment of type 2 diabetes or obesity.
机译:口服施用的靶向纳米颗粒具有大量潜在的生物医学应用,并显示了口服药物递送的一些推定优势,例如保护脆弱的药物或改变药物的药代动力学。尽管具有这些优点,但是通过纳米颗粒的口服药物递送仍然具有挑战性。粒径和表面性能的优化以及配体接枝的靶向已显示可增强纳米颗粒在肠道上皮细胞中的转运。在此,讨论了在胃肠道中稳定的非肽配体例如肽模拟物,凝集素模拟物,糖和维生素的不同接枝策略。我们证明这些非肽配体的嫁接允许纳米粒子被靶向到M细胞,肠细胞,免疫细胞或L细胞。我们表明,这些嫁接的纳米粒子可能是有针对性的媒介物,可通过靶向M细胞或用于治疗性蛋白的口服疫苗接种。我们建议靶向L细胞可用于治疗2型糖尿病或肥胖症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号